The aim of METAJOINT concerns the scanning with META-scan of a limited set of 5 patients for three imaging methods (total number of 15 patients) to scan for respectively phosphorus, sodium and deuterium. All three methods provide information regarding metabolic aspects of the joint.
GAG-CEST image, Brinkhof et al.
METAJOINT will deliver three potential new MRI-based outcome measures and biomarkers for osteoarthritis, which may also differentiate the general osteoarthritis patients in subtypes with a different disease origin and hence, different treatment strategies. For pharma trials in osteoarthritis this differentiation in phenotypes is of utmost importance. The UMC Utrecht is coordinating a large EU-IMI project (APPROACH, 15 M€) in collaboration with three pharma companies; GSK(Brentford, UK), Servier (Paris, Fr), Merck (Darmstadt, GE). The main aim of this project and interest of the pharma companies is to get access to better outcomes measure in order to identify the phenotype and follow the status of osteoarthritis to eventually set up better clinical trials. In other words, to find the right patient for the right therapy and measuring the right outcome measures.
METAJOINT will potentially provide such outcomes measures.